EGFR and colorectal cancer: EGFR-directed therapy with agents like cetuximab and panitumumab is a cornerstone in treating colorectal cancers with a wild-type EGFR status, as mutations in the EGFR pathway, such as RAS mutations, can negate the benefits of such treatments [15].